The ruthenium complexes cis -(dichloro)tetramineruthenium(III) chloride and cis -tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549)

Lung cancer is one of the leading causes of death in the world, and non-small cell lung carcinoma accounts for approximately 75–85 % of all lung cancers. In the present work, we studied the antitumor activity of the compound cis -(dichloro)tetramineruthenium(III) chloride { cis -[RuCl 2 (NH 3 ) 4 ]Cl} against human lung carcinoma tumor cell line A549. The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human lung carcinoma cell lines A549 treated with cis CarboPt, cis CRu(III) and cis DRu(III). The ruthenium-based coordinated complexes presented low cytotoxic and antiproliferative activities, with high IC 50 values, 196 (±15.49), 472 (±20.29) and 175 (±1.41) for cis CarboPt, cis CRu(III) and cis DRu(III), respectively. The tested compounds induced apoptosis in A549 tumor cells as evidenced by caspase 3 activation, but only at high concentrations. Results also revealed that the amplification of P-gp gene is greater in A549 cells exposed to cis CarboPt and cis CRu(III) than cis DRu(III). Taken together all these results strongly demonstrate that MDR-1 over-expression in A549 cells could be associated to a MDR phenotype of these cells and moreover, it is also contributing to the platinum, and structurally-related compound, resistance in these cells. The identification and characterization of novel mechanisms of drug resistance will enable the development of a new generation of anti-cancer drugs that increase cancer sensitivity and/or represent more effective chemotherapeutic agents.